8-K: Galectin Therapeutics Reports Promising Belapectin Data and First Quarter 2025 Financial Results

Galectin Therapeutics announced encouraging data from its belapectin program for MASH cirrhosis and portal hypertension, along with its financial results for the first quarter of 2025.

Summary

• Galectin Therapeutics reported its financial results for the three months ended March 31, 2025, and provided a business update.
• The company is focused on advancing additional analyses for belapectin, a drug targeting galectin-3 for MASH and fibrosis.
• Data from the NAVIGATE trial presented at EASL showed a clinically significant response in Fibroscan measurements with the 2 mg/kg dose of belapectin.
• The 2 mg/kg dose also led to a significantly lower incidence of new varices compared to placebo in the per protocol population.
• Liver stiffness measurements (LSM) showed that approximately double the number of patients demonstrated worsening of liver stiffness on placebo compared to on belapectin.
• The 2 mg/kg population and the 4 mg/kg population showed statistically significant changes from baseline on Fibroscan data, while the placebo population did not.
• As of March 31, 2025, the company had $7.4 million in cash and cash equivalents.
• The company has $11 million remaining available under two lines of credit from its chairman to fund operations.
• The company believes it has sufficient cash to fund currently planned operations and research and development activities through August 2025.
• Research and development expenses for the quarter ended March 31, 2025, were $6.5 million, compared with $8.1 million for the same period in 2024.
• The company reported a net loss applicable to common stockholders of $9.6 million, or ($0.15) per share, for the quarter ended March 31, 2025, compared to a net loss of $11.5 million, or ($0.19) per share for the quarter ended March 31, 2024.

Sentiment

Score: 7

Explanation: The document presents positive clinical data for belapectin and a decrease in net loss, but also highlights the company's limited cash runway and the need for potential partnerships or further funding. The sentiment is cautiously optimistic.

Positives

• Belapectin demonstrates potential as a treatment for MASH cirrhosis and portal hypertension.
• NAVIGATE trial data and biomarker analysis presented at EASL were well-received.
• The company has sufficient cash to fund operations through August 2025.
• Research and development expenses decreased compared to the same period in the previous year.
• Net loss per share improved compared to the same period in the previous year.

Negatives

• The company reported a net loss of $9.6 million for the quarter ended March 31, 2025.
• The company's cash and cash equivalents decreased from $15.120 million at the end of 2024 to $7.431 million as of March 31, 2025.

Risks

• The company's future financial performance could differ significantly from management's expectations.
• The company may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development.
• The company's current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly.
• The company may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials.
• The company has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations.

Future Outlook

The company hopes that its development program for belapectin will lead to the first therapy for the treatment of MASH with cirrhosis and that its lead compounds will be successful in cancer immunotherapy and other therapeutic indications. The company believes it has sufficient cash to fund currently planned operations and research and development activities through August 2025.

Management Comments

• 'This quarter, we remained laser-focused on advancing additional analyses for belapectin,' stated Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics.
• Mr. Lewis added, 'I was extremely encouraged by the feedback we received last week at the European Association for the Study of the Liver (EASL), specifically that we successfully demonstrated a clinically significant response in a key biomarker (Fibroscan) that is used to support outcomes in MASH trials at every stage of disease progression.'
• Khurram Jamil, M.D., Chief Medical Officer, added 'We were pleased to present the analysis of the NAVIGATE trial coupled with biomarker analysis to the scientific community and industry stakeholders at EASL.'
• Mr. Lewis added, 'We are pleased to share that after a complete analysis of all existing valid Fibroscan data, we observed several important findings.'

Industry Context

The announcement highlights Galectin Therapeutics' efforts to address the growing unmet medical need for treatments for MASH-associated liver cirrhosis and portal hypertension. The company is positioning belapectin as a potential first-in-class therapy in this space.

Comparison to Industry Standards

• The document references published trials in MASH populations where categorical increases in liver stiffness measurement (LSM) result in significantly increased rates of liver complications.
• The company is using liver stiffness measurements (LSM), assessed using FibroScan, and a commonly used analytical method for this test i.e. Mixed Model for Repeated Measures (MMRM), incorporating all clean and verified assessments collected throughout NAVIGATE.

Stakeholder Impact

• Positive clinical trial results could benefit patients with MASH cirrhosis and portal hypertension.
• Shareholders may react positively to the promising data and improved financial performance.
• Employees may be encouraged by the progress of the company's lead drug candidate.

Next Steps

• The company looks forward to sharing more biomarker data as it becomes available.
• The company seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development.
• Advancement of additional clinical programs is largely dependent on finding a suitable partner.

Key Dates

Keywords

Galectin Therapeutics, belapectin, MASH, cirrhosis, portal hypertension, NAVIGATE trial, FibroScan, liver stiffness, clinical trial, financial results